CMS adds flexibilities to final Aduhelm NCD, but usage could be rare

Why This Topic Matters

The article matters because it describes a CMS coverage decision that could influence access to a costly new class of Alzheimer’s treatments and set expectations for future Medicare policy. It is useful for coding, reimbursement, compliance, and health policy audiences following coverage limits, trial-based payment pathways, and federal program impacts.

Article Sections

1. CMS final coverage decision

   Summarizes the final national coverage determination and the main coverage framework CMS adopted after the proposed decision. It also notes how the final policy differs from the earlier proposal at a high level.

2. Pushed by FDA

   Reviews the FDA approval context and the broader regulatory backdrop that shaped CMS’s decision. It discusses the relationship between accelerated approval, post-approval study expectations, and Medicare coverage policy.

3. Cost, availability problems

   Explores concerns about the cost of treatment, the availability of qualifying studies, and potential effects on future Alzheimer’s drug development. It also highlights policy and access concerns raised by industry and patient advocates.